Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics	cancer, neoplasm	Active, not recruiting	Phase 1	2025-07-08		NCT06980454

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanghai Henlius Biotech	58

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Xuzhou Medical University	Jiangsu	China	1
Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu	Xuzhou	China	1

Clinical trials